anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a traditional Chinese medicine powder, and a preparation method and an application thereof. The powder comprises the following components, by mass: 15-30 parts of betel nut, 10-20 parts of rhubarb, 10-20 parts of stir-fried hawthorn, 10-20 parts of black pharbitis seed, 10-20 parts of white pharbitis seed, 25-50 parts of common phellinus fungus, 10-20 parts mix-fried licorice root, 10-20 parts of panax notoginseng, and 1-5 parts of purging croton seed. The traditional Chinese medicine powder is orally taken, and can be used for treating digestive system diseases. With the powder, gastroenteritis can be eliminated, gastrointestinal tract garbage can be removed, and internal toxins can be discharged. The medicine powder has the advantages of clear formula, simple preparation process, short treatment course, simple application method, and easy implementation by patients. More importantly, compared with existing Western medicines and traditional Chinese medicines, the medicine powder provided by the invention has a fast and reliable effect in treating the digestive system diseases, and has prevention and treatment effect against tumor or cancer.
BACKGROUND AND OBJECTIVES: HLA-DRB1*15:01 (DR15) and MERTK are 2 risk genes for multiple sclerosis (MS). The variant rs7422195 is an expression quantitative trait locus for MERTK in CD14+ monocytes; cells with phagocytic and immunomodulatory potential. We aimed to understand how drivers of disease risk and pathogenesis vary with HLA and MERTK genotype and disease activity.
METHODS: We investigated how proportions of monocytes vary with HLA and MERTK genotype and disease activity in MS. CD14+ monocytes were isolated from patients with MS at relapse (n = 40) and 3 months later (n = 23). Healthy controls (HCs) underwent 2 blood collections 3 months apart. Immunophenotypic profiling of monocytes was performed by flow cytometry. Methylation of 35 CpG sites within and near the MERTK gene was assessed in whole blood samples of individuals experiencing their first episode of clinical CNS demyelination (n = 204) and matched HCs (n = 345) using an Illumina EPIC array.
RESULTS: DR15-positive patients had lower proportions of CD14+ MERTK+ monocytes than DR15-negative patients, independent of genotype at the MERTK SNP rs7422195. Proportions of CD14+ MERTK+ monocytes were further reduced during relapse in DR15-positive but not DR15-negative patients. Patients homozygous for the major G allele at rs7422195 exhibited higher proportions of CD14+ MERTK+ monocytes at both relapse and remission compared with controls. We observed that increased methylation of the MERTK gene was significantly associated with the presence of DR15.
DISCUSSION: DR15 and MERTK genotype independently influence proportions of CD14+ MERTK+ monocytes in MS. We confirmed previous observations that the MERTK risk SNP rs7422195 is associated with altered MERTK expression in monocytes. We identified that expression of MERTK is stratified by disease in people homozygous for the major G allele of rs7422195. The finding that the proportion of CD14+ MERTK+ monocytes is reduced in DR15-positive individuals supports prior data identifying genetic links between these 2 loci in influencing MS risk. DR15 genotype-dependent alterations in methylation of the MERTK gene provides a molecular link between these loci and identifies a potential mechanism by which MERTK expression is influenced by DR15. This links DR15 haplotype to MS susceptibility beyond direct influence on antigen presentation and suggests the need for HLA-based stratification of approaches to MERTK as a therapeutic target.
BACKGROUND/INTRODUCTION: Esophagogastric junction outflow obstruction (EGJOO) is a condition characterized by poor relaxation of the lower esophageal sphincter (LES), which can manifest as dysphagia and chest pain. The best treatment of EGJOO is unknown as some patients improve without any specific therapy, whereas some patients undergo invasive therapy. Currently, prognostic factors are lacking. We aimed to assess the long-term prognosis and predictors of dysphagia and chest pain by the rapid drink challenge and solid bolus swallows in EGJOO.
METHODS: We retrospectively assessed high-resolution esophageal manometries (HRM) performed at our center between 2015 and 2018. The patients completed a dysphagia and chest pain questionnaire a median of 34 months after the HRM/baseline assessment, including the Impaction dysphagia questionnaire-10 (IDQ-10) complemented with questions regarding chest pain and esophageal treatments. Symptoms were compared with HRM findings.
RESULTS: In all, 980 HRMs were analyzed and 66 (6.5%) were identified as having HRM findings compatible with EGJOO. Of these, 27 patients with EGJOO (41%) completed the follow-up questionnaires and had no exclusion criteria, and 70% of these patients had dysphagia and 44% chest pain at least once a week. Dysphagia at follow-up was more common in patients with elevated integrated relaxation pressure (IRP) on all three HRM metrics (water swallows, solid bolus swallows, and rapid drink challenge) (p = 0.03, odds ratio: 8.4 (95% CI: 1.2-56.0)), but this was not seen for chest pain (p = 0.45). Abnormal motility patterns on rapid drink challenge or solid bolus swallows were not associated with dysphagia or chest pain at follow-up.
CONCLUSIONS: Having a high IRP on three HRM metrics-water swallows, solid bolus swallows, and rapid drink challenge-is associated with a worse prognosis in patients with EGJOO and could potentially be used to select candidates suitable for invasive procedures.
Before commencing treatment with ELIDEL Cream, 1%, bacterial or viral infections at treatment sites should be resolved. Trials have not evaluated the safety and efficacy of ELIDEL Cream, 1% in the treatment of clinically infected atopic dermatitis.

While patients with atopic dermatitis are predisposed to superficial skin infections including eczema herpeticum (Kaposi’s varicelliform eruption), treatment with ELIDEL Cream, 1% may be independently associated with an increased risk of varicella zoster virus infection (chickenpox or shingles), herpes simplex virus infection, or eczema herpeticum.

In clinical trials, 15/1544 (1%) cases of skin papilloma (warts) were observed in subjects using ELIDEL Cream, 1%. The youngest subject was age 2 and the oldest was age 12. In cases where there is worsening of skin papillomas or they do not respond to conventional therapy, discontinuation of ELIDEL Cream, 1% should be considered until complete resolution of the warts is achieved.
Of the 2,459 patients who received DARZALEX at the recommended dose, 38% were 65 to 74 years of age, and 15% were 75 years of age or older. No overall differences in effectiveness were observed between these patients and younger patients. The incidence of serious adverse reactions was higher in older than in younger patients [see Adverse Reactions (6.1)] . Among patients with relapsed and refractory multiple myeloma (n=1,213), the serious adverse reactions that occurred more frequently in patients 65 years and older were pneumonia and sepsis. Within the DKd group in CANDOR, fatal adverse reactions occurred in 14% of patients 65 years and older compared to 6% of patients less than 65 years. Among patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (n=710), the serious adverse reaction that occurred more frequently in patients 75 years and older was pneumonia.
PURPOSE: To form microcapsulated dry particulates in a dry powder form by adhering a slurry obtd. by bringing the microcapsulated dry particles into contact with a surfactant or the like to a carrier substrate, then evaporating the surfactant. CONSTITUTION: The slurry is prepd. by bringing the microcapsulated dry particulates into contact with a precipitation preventing agent and the surfactant and this slurry is adhered to the carrier substrate. The surfactant is then evaporated from the slurry on the surface to form the microcapsulated liquid in a dried state in such a manner that the liquid is not substantially adhered and fixed to the carrier substrate and is made desorbable from the carrier substrate, by which the carrier adhered with the microcapsulated liquid is produced. The adequate examples of the carrier substrate include coated paper, uncoated paper, plastic films or the like.
<P>PROBLEM TO BE SOLVED: To provide a therapeutic/prophylactic agent having high safety to human bodies.  <P>SOLUTION: The therapeutic/prophylactic agent for diabetic nephropathy comprises a physically treated material or a chemically treated material of hard tissue of squid as an active ingredient. Shell and tendon are quoted as examples of the hard tissue of the squid. Since the therapeutic/prophylactic agent for diabetic nephropathy hardly has action lowering blood glucose level and exhibits the effect only on diabetic nephropathy, the agent is especially useful when it is not required to lower the glucose level. The therapeutic/prophylactic agent for diabetic nephropathy can be used as a functional food and a medicine.  <P>COPYRIGHT: (C)2007,JPO&INPIT
A controller (150) for selecting images for presentation includes a memory (151), a processor (152) and a receiver. The memory (151) stores instructions. The processor (152)executes the instructions. The receiver receives a stream of a plurality of images. When executed by the processor (152), the instructions cause the controller (150) to apply trained artificial intelligence to the plurality of images and generate, based on the trained artificial intelligence, a 1-dimensional stream of a plurality of values corresponding respectively to the plurality of images. Each of the plurality of values of the 1-dimensional stream indicates a significance of a corresponding image of the plurality of images according to the trained artificial intelligence. The instructions also cause the controller (150) to output the plurality of values of the 1-dimensional stream for display with the plurality of images.
Delirium is an acute confusional state characterized by fluctuating mental status, inattention, and either disorganized thinking or an altered level of consciousness. The prevalence of delirium in elderly patients is approximately 10% in emergency department (ED) patients. Several hospital-based studies have shown delirium to be associated with worsening mortality,longer hospital length of stay, higher health care costs,and poorer long-term functional and cognitive function.

However, delirium in the ED remains poorly understood. Specifically, its natural course is not well characterized and represents a critical gap in knowledge. Improving our understanding is paramount for several reasons. If the majority of delirium persists beyond the ED and is associated with long-term adverse outcomes, then routine delirium surveillance in the busy ED environment can be justified. Understanding the natural course may also help physicians identify delirious patients at highest risk for adverse outcomes and would be the focus of future delirium interventions. Lastly, we don't know if all patients with delirium require an admission. Understanding the natural course may help identify delirious patients that can be safely discharged home and those who require a hospital admission.

Given this paucity of data, we are conducting this study with the following specific aims: 1) To describe the frequency in which delirium in the ED persists into hospitalization and determine how patient factors and clinical factors affect delirium persistence. 2) To determine how ED delirium duration affects 6-month outcomes. To achieve these aims, we will perform a prospective cohort study thatwill enroll 125 older ED patients with delirium and a random selection of 125 older ED patients without delirium; both groups will comprise of admitted ED patients only. Once enrolled in the ED, we will assess patients for 7 days during hospitalization and perform phone follow-up at 6-months.
This is a multi-center (conducted in more than one center), open-label (all people know the identity of the intervention), single-arm study to investigate safety and efficacy of abiraterone. The study consists of 3 phases: Screening phase (consists of 14 days before study commences on Day -1); Treatment phase (consists of 28-daily dosing cycles wherein abiraterone 1000 milligram \[mg\] once daily and 5 mg prednisolone twice daily will be given until disease progression or unacceptable toxicity is observed); and Follow-up phase (up to 5 years or until survival after the first dose of study drug). Abiraterone will be administered orally daily as at least 1 hour before the meal or 2 hours after the meal. Dose reduction will be allowed at the Investigator's discretion but not lower than 500 mg per day. Participants will discontinue study treatment at disease progression unless, in the Investigator's opinion, it is deemed that the participants will continue to derive benefit from abiraterone. Efficacy will be evaluated primarily through decline in prostate-specific antigen (substance in blood that is measured to check for prostate cancer) after 12 weeks of therapy. Participants' safety will be monitored throughout the study.
OBJECTIVES: Bleeding after endoscopic submucosal dissection (ESD) for gastric tumors in patients taking antithrombotic drugs, in particular direct oral anticoagulants (DOACs), remains unresolved; therefore, we evaluated the risk factors for post-ESD bleeding and drug differences in patients taking DOACs.
METHODS: We included 278 patients taking antithrombotic drugs who underwent gastric ESD between January 2017 and March 2022. Antithrombotic drugs were withdrawn following the 2017 guidelines (Appendix on anticoagulants including DOACs). To further clarify differences in antithrombotic agents' effects, the peri-cancerous mucosa in the resected specimen was pathologically evaluated according to the Updated Sydney System. Multivariate analysis was performed to assess the risk of post-ESD bleeding.
RESULTS: The incidence of post-ESD bleeding in patients taking DOACs was 19.6% (10/51). Among patients taking antithrombotic drugs, DOACs were identified as a possible factor involved in post-ESD bleeding (odds ratio [OR] 4.92). Among patients taking DOACs, possible factors included resection length diameter ≥30 mm (OR 3.72), presence of neutrophil infiltration (OR 2.71), lesions occurring in the lower third of stomach (OR 2.34), and preoperative antiplatelet use (OR 2.22). Post-ESD bleeding by DOAC type was 25.0% of patients (4/16) receiving apixaban, in 20.0% (3/15) receiving edoxaban, in 21.4% (3/14) receiving rivaroxaban, and in none of those receiving dabigatran.
CONCLUSIONS: The administration of DOACs was shown to be a possible factor involved in post-ESD bleeding, and risk factors for patients taking DOACs included neutrophil infiltration. The pharmacological differences in the effects of DOACs contributing to bleeding in gastric ulcers suggest comparatively less bleeding with dabigatran after ESD.
The development of a potentially life-threatening serotonin syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions have been reported with SSRIs, SNRIs, MAOIs, and other serotonergic drugs used as monotherapy, including mirtazapine tablets, but particularly with concomitant use of serotonergic drugs (including triptans) with drugs which impair metabolism of serotonin (including MAOIs), or with antipsychotics or other dopamine antagonists. Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Serotonin syndrome, in its most severe form can resemble neuroleptic malignant syndrome, which includes hyperthermia, muscle rigidity, autonomic instability with possible rapid fluctuation of vital signs, and mental status changes. Patients should be monitored for the emergence of serotonin syndrome or NMS-like signs and symptoms. The concomitant use of mirtazapine tablets with MAOIs intended to treat depression is contraindicated [see CONTRAINDICATIONS].   


If concomitant treatment of mirtazapine tablets with a 5-hydroxytryptamine receptor agonist (triptan) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.

The concomitant use of mirtazapine tablets with serotonin precursors (such as tryptophan) is not recommended.

Treatment with mirtazapine tablets and any concomitant serotonergic or antidopaminergic agents, including antipsychotics, should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.
The invention belongs to the technical field of health tea, and particularly relates to health tea for losing weight, reducing blood fat, blood pressure and blood sugar. The health tea comprises the following components: fructus Arctii, folium Ginkgo, folium Nelumbinis, semen Cassiae, herba Gynostemmatis, stigma Maydis, fructus crataegi, Corni fructus, fructus Lycii, radix rehmanniae, radix Paeoniae alba, cortex moutan, Ginseng radix, radix Puerariae, and Notoginseng flower. The health tea has scientific and reasonable formula and rich medicine sources, not only accords with the characteristics of the theory, method, formula and medicine of the traditional Chinese medicine, but also has the basis of modern medicine and pharmacology. The health tea of the invention promotes vasodilatation, promotes sweat gland secretion, promotes blood circulation, dredges channels and collaterals, promotes blood circulation to remove blood stasis, relieves exterior syndrome and dispels cold, thereby activating cell activity. The health tea of the invention regulates nerves, regulates internal organs, regulates balance, regulates five internal organs, clears and activates the channels and collaterals, has no toxic or side effect on organisms, can restore and enhance the immune system of the organisms and can restore the health of the organisms. The health tea is suitable for popularization and drinking in the masses of people.
PURPOSE:To obtain the subject inhibitor containing a protocyanidine as active ingredient. CONSTITUTION:This Maillard reaction inhibitor contains, as active ingredient, a protocyanidine found in e.g. grape extracts, pref. a protocyanidine as a dimer to decamer (esp. dimer to tetramer) composed of a constituent unit of flavan-3-ol or flavan-3,4-diol of the formula (R1 is H or OH; R2-R4 each are H, OH, methoxy; R5 is H, galloyl or glycopyranosyl). This inhibitor can suppress collagen crosslinking known also as sensile crosslinking which contributes to skin hardening or wrinkle development and pigmentation which contributes to dark skin color and can be applicable as a skin external preparation or cosmetic.
Part C dose expansion of tuspetinib in combination with venetoclax is planned for 2 dose levels. The initial tuspetinib dose will be 80 mg.
Evidence-based treatments for depression have rarely been studied in community settings where low-income and ethnic minority patients receive care. Among the most in need of effective treatments are depressed women with histories of early interpersonal trauma, who suffer disproportionate burden characterized by chronic depression, multiple comorbidities, and marked interpersonal difficulties. The aim of this randomized controlled trial (RCT), based in a community mental health center, is to evaluate the effectiveness of Interpersonal Psychotherapy-Trauma in Community Settings (IPT-TCS). IPT-TCS is Interpersonal Psychotherapy with modifications specifically designed for the treatment of depressed patients with trauma histories seen in community settings. This trial (n=180) will compare IPT-TCS to active treatment as usual (TAU) for women with major depression and histories of childhood sexual abuse. We hypothesize that IPT-TCS will be more effective than TAU in reducing depression at 32-weeks after treatment assignment. Improvements in social functioning, health-related functioning, post-traumatic stress symptoms, and mental health functioning are also expected. To monitor post-treatment course, outcome variables will be assessed at 6-month intervals over a 2-year period, and longer-term effects will be examined via repeated-measure analyses. This trial is designed to provide definitive results regarding the effectiveness of IPT-TCS compared to usual care in a community mental health center.
PURPOSE: To obtain a detergent composition which is superior to conventional detergents in the texture of foam, such as slipperiness and creaminess of foam, and foam breakability and is excellent in safety for the skin by blending a hydroxyalkylated cyclodextrin(HAC) and a maltitol hydroxy aliphatic ether (MHE). CONSTITUTION: An HAC represented by formula I is added in an amount of 0.5-50wt.% based on the total amount of surfactant in the detergent composition, and an MHE represented by formula II (wherein A is a residue obtained by removing n OH groups from maltitol; R<1> and R<2> are each II, 1-20C alkyl or branched alkyl; and n is 1 or 2) in an amount of 0.1-10wt.% based on the detergent composition. The degree of substitution of the HAC by hydroxyalkyl groups is preferably 1 to 14. The higher the degree of substitution, the higher the solubility in water. β-cyclodextrin is usually used as the cyclodextrin. The use of a suitable combination of anionic and amphoteric surfactants is preferable although anionic and amphoteric surfactants may be used alone.
A first patient intervention is identified. The first patient intervention regards a first patient record that includes one or more attributes related to a first patient. The first patient intervention is transmitted to a first program split of a secure multi-party computation. A conflict is detected in the first patient intervention and an existing medical situation regarding the first patient. The conflict is detected by the first program split of the secure multi-party computation and by a third program split of the secure multi-party computation. Based on the detected conflict, a notification is generated by the first program split. The notification is based on the detected conflict. The notification based on the detected conflict is provided to a first client.
Bilateral medial medullary infarction is a rare subtype of stroke.The typical heart-shaped appearance on magnetic resonance imaging is pathognomonic for bilateral medial medullary syndrome. Vertebrobasilar dolichoectasia is a condition characterized by tortuous dilatation and marked enlargement of the basilar and vertebral arteries, and it may cause posterior circulation infarction. We present the case of a 55-year-old female patient with complaints of speech disorder, regression in consciousness, and difficulty breathing. Diffusion-weighted imaging examination was normal on arrival. In the cranial imaging after 24 hours, acute infarction was observed in the bilateral medial medullary area. Time-of-flight magnetic resonance angiography revealed vertebrobasilar dolichoectasia. In this report, a case of bilateral medial medullary infarction with a unique radiological appearance accompanied by vertebrobasilar dolichoectasia, which is rarely reported in the literature, is presented. Keywords: Stroke, infarct, bilateral medial medullary infarction, heart appearance.